Q2 2020 13F Holders as of 6/30/2020
-
Type / Class
-
Equity / Common
-
Shares outstanding
-
229M
-
Number of holders
-
76
-
Total 13F shares, excl. options
-
55.5M
-
Shares change
-
-7.92M
-
Total reported value, excl. options
-
$48.3M
-
Value change
-
-$6.85M
-
Number of buys
-
32
-
Number of sells
-
-35
-
Price
-
$0.87
Significant Holders of Lineage Cell Therapeutics, Inc. - Common (LCTX) as of Q2 2020
98 filings reported holding LCTX - Lineage Cell Therapeutics, Inc. - Common as of Q2 2020.
Lineage Cell Therapeutics, Inc. - Common (LCTX) has 76 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 55.5M shares
of 229M outstanding shares and own 24.26% of the company stock.
Largest 10 shareholders include BROADWOOD CAPITAL INC (34M shares), VANGUARD GROUP INC (5.23M shares), Defender Capital, LLC. (4.65M shares), Prescott General Partners LLC (1.85M shares), BlackRock Inc. (1.59M shares), GEODE CAPITAL MANAGEMENT, LLC (1.02M shares), JANE STREET GROUP, LLC (996K shares), Russell Investments Group, Ltd. (762K shares), Northeast Financial Consultants Inc (524K shares), and RENAISSANCE TECHNOLOGIES LLC (492K shares).
This table shows the top 76 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.